Phio Pharmaceuticals Corp.
PHIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $2 | $1,074 | $0 | $0 |
| Gross Profit | -$2 | -$1,074 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,181 | $1,074 | $886 | $985 |
| G&A Expenses | $0 | $1,235 | $986 | $0 |
| SG&A Expenses | $1,322 | $1,235 | $986 | $689 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1,074 | $0 | $0 |
| Operating Expenses | $2,503 | $1,235 | $1,872 | $1,674 |
| Operating Income | -$2,505 | -$2,309 | -$1,872 | -$1,674 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $113 | $143 | $103 | $48 |
| Pre-Tax Income | -$2,392 | -$2,166 | -$1,769 | -$1,626 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,392 | -$2,166 | -$1,769 | -$1,626 |
| % Margin | – | – | – | – |
| EPS | -0.44 | -0.45 | -41,070.15 | -0.37 |
| % Growth | 2.2% | 100% | -11,099,940.5% | – |
| EPS Diluted | -0.44 | -0.45 | -41,070.15 | -0.37 |
| Weighted Avg Shares Out | 54,686 | 4,795 | 0 | 7,875 |
| Weighted Avg Shares Out Dil | 54,686 | 4,795 | 0 | 7,875 |
| Supplemental Information | – | – | – | – |
| Interest Income | $113 | $119 | $125 | $231 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $1 | $0 | $0 |
| EBITDA | -$2,390 | -$2,309 | -$1,769 | -$1,626 |
| % Margin | – | – | – | – |